Literature DB >> 12632864

Testicular cancer: maintaining the high cure rate.

Derek Raghavan1.   

Abstract

The management of germ cell tumors has advanced dramatically, with cure rates approaching 90% to 95%. Treatment of stage I/A seminomas generally includes orchiectomy and adjuvant radiotherapy. Treatment of stage I/A nonseminomatous germ cell tumors involves orchiectomy followed by retroperitoneal lymph node dissection or active surveillance. One of the major advances has been the introduction of cisplatin-based chemotherapy for metastatic disease and the development of a system of risk attribution. The logical management of any patient with curable disease is to provide curative therapy and then follow the patient in a structured manner, to diagnose and treat any complications in a timely manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12632864

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  9 in total

Review 1.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  K-RAS and N-RAS mutations in testicular germ cell tumors.

Authors:  Bekir Muhammet Hacioglu; Hilmi Kodaz; Bulent Erdogan; Ahmet Cinkaya; Ebru Tastekin; Ilhan Hacibekiroglu; Esma Turkmen; Osman Kostek; Ezgi Genc; Sernaz Uzunoglu; Irfan Cicin
Journal:  Bosn J Basic Med Sci       Date:  2017-05-20       Impact factor: 3.363

3.  Molecular genetics of testicular germ cell tumors.

Authors:  Yuri Sheikine; Elizabeth Genega; Jonathan Melamed; Peng Lee; Victor E Reuter; Huihui Ye
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

4.  AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway.

Authors:  Hailiang Xu; Yunyun Feng; Zhankui Jia; Jinjian Yang; Xueren Lu; Jun Li; Mingliang Xia; Chunru Wu; Yonggang Zhang; Jianhua Chen
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

5.  Primary extragonadal germ cell tumor: A case report on prostate seminoma.

Authors:  Wei Zheng; Lina Wang; Deyong Yang; Kun Fang; Xiaochi Chen; Xuejian Wang; Xiancheng Li; Ziyao Li; Xishuang Song; Jianbo Wang
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

Review 6.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

Review 7.  Polymorphic transporters and platinum pharmacodynamics.

Authors:  Jason A Sprowl; Rachel A Ness; Alex Sparreboom
Journal:  Drug Metab Pharmacokinet       Date:  2012-09-18       Impact factor: 3.614

Review 8.  Testicular mixed germ cell tumor presenting with seizure as the initial symptom: a case report and literature review.

Authors:  Syuan-Hao Syu; Chia-Lun Chang; Hung-Jen Shih
Journal:  Int Braz J Urol       Date:  2019 May-Jun       Impact factor: 1.541

9.  Evaluation of oxaliplatin-induced pulmonary toxicity in rats.

Authors:  Serdar Kalemci; Ozgür Tanrıverdi; Abdullah Şimşek; Saliha Aksun; Ozgür I Celik; Sabri Barutca; Arife Zeybek; Buket Demirci
Journal:  Contemp Oncol (Pozn)       Date:  2019-10-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.